It is well known that the response of CML patients to the drug imatinib mesylate (a tyrosine kinase inhibitor that inhibits BCR-ABL) diminishes during disease progression [30]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.